Kane Biotech Inc. (TSXV:KNE)
Canada flag Canada · Delayed Price · Currency is CAD
0.0200
-0.0100 (-33.33%)
Aug 10, 2026, 3:31 PM EST

Kane Biotech Financials Overview

Millions CAD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.060.432.080.152.671.61
Revenue Growth
-97.60%-79.44%1296.75%-94.42%65.97%19.84%
Gross Profit
-0.05-00.870.111.410.57
Operating Income
-0.67-2.65-3.92-3.36-3.36-4.88
Net Income
-2.22-2.726.17-5.27-3.82-4.85
Earnings Per Share
-0.01-0.02-0.02-0.04-0.03-0.04
EPS Growth
------

Revenue by Segment

Fiscal YearTTMFY 2025FY 2024FY 2023
Period EndingMar '26 Dec '25 Dec '24 Dec '23
Animal Health
-0.412.492.78
Human Health
0.050.020.680.04
Total
0.060.433.162.82

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.40.90.360.751.11.15
Total Debt
1.922.32.189.256.864.71
Net Cash (Debt)
-1.52-1.4-1.82-8.5-5.75-3.56
Net Cash Growth
------
Net Cash Per Share
-0.01-0.01-0.01-0.07-0.05-0.03

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-2.64-3.26-4.11-2.08-3.04-2.29
Capital Expenditures
0.01-0-0.02-0.01-0.01-0.19
Free Cash Flow
-2.63-3.26-4.14-2.09-3.05-2.48
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-80.22%-0.15%41.91%73.48%52.96%35.36%
Operating Margin
-1149.49%-620.25%-188.53%-2253.58%-126.06%-303.75%
Pretax Margin
-434.91%-528.28%-136.57%-2253.58%-99.44%-248.30%
Profit Margin
-257.73%-636.00%-151.91%-2253.58%-99.44%-248.30%
FCF Margin
-4487.53%-761.99%-198.77%-1403.79%-114.40%-153.99%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
70.0216.987.2870.804.2111.43